Atypical antipsychotics are pharmaceutical drugs used to treat schizophrenia. Common side
effects are weight gain, insulin resistance, and abnormal blood lipids. This increases the
risk for type 2 diabetes and cardiovascular disease in patients taking these drugs. In
particular, olanzapine is a highly effective therapy for schizophrenia but is commonly
associated with metabolic disturbances. It has previously been shown that the negative
effects on insulin sensitivity and glucose metabolism occur even after a single dose,
independently of weight gain. These effects may be mediated by blocking the dopamine (D2)
receptor. In this study the research team is investigating whether a single dose of
olanzapine alters postprandial lipid metabolism after a high-fat drink. Olanzapine
administered along with the high-fat drink will be compared to placebo or olanzapine plus
bromocriptine (an activator of the D2 receptor).